M. Cremonesi

ORCID: 0000-0002-8817-2186
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Cancer Treatment and Pharmacology
  • Atherosclerosis and Cardiovascular Diseases
  • Cardiac Fibrosis and Remodeling
  • Breast Cancer Treatment Studies
  • Cancer Diagnosis and Treatment
  • Radiomics and Machine Learning in Medical Imaging
  • Lung Cancer Treatments and Mutations
  • HER2/EGFR in Cancer Research
  • Colorectal Cancer Treatments and Studies
  • SARS-CoV-2 and COVID-19 Research
  • Cancer survivorship and care
  • Long-Term Effects of COVID-19
  • Adipose Tissue and Metabolism
  • COVID-19 Clinical Research Studies
  • Pain Management and Opioid Use
  • Immune Cell Function and Interaction
  • Chemotherapy-induced cardiotoxicity and mitigation
  • Immune cells in cancer
  • Erythropoietin and Anemia Treatment
  • Heart Failure Treatment and Management
  • Bioinformatics and Genomic Networks
  • Metabolomics and Mass Spectrometry Studies
  • Medical Imaging Techniques and Applications
  • Radiopharmaceutical Chemistry and Applications
  • Lung Cancer Research Studies

IRCCS Humanitas Research Hospital
2021-2025

Humanitas University
2019-2023

Istituti di Ricovero e Cura a Carattere Scientifico
2017-2020

Vita-Salute San Raffaele University
2017

Azienda Ospedaliera Treviglio
2004-2016

European Institute of Oncology
1997-2016

Cerner (United States)
2007

Inflammation is a key component of cardiac disease, with macrophages and T lymphocytes mediating essential roles in the progression to heart failure. Nonetheless, little insight exists on other immune subsets involved cardiotoxic response.Here, we used single-cell RNA sequencing map composition standard murine nonischemic, pressure-overload failure model. By focusing our analysis CD45+ cells, obtained higher resolution identification cell heart, at early late stages disease controls. We then...

10.1161/circulationaha.119.041694 article EN Circulation 2019-10-30

Immune checkpoint inhibitors (ICIs) revolutionized cancer therapy, yet require management of immune-related adverse events (irAEs). Fulminant myocarditis is a rare irAE, but lower-severity cardiac are being reported more frequently, leading to an unmet need for irAE prevention, early diagnosis, and treatment, especially long-life-expectancy patients. We recruited 57 patients, stratified according therapy regime (monotherapy (30%) or combination (33%) cohort) history disease presence at least...

10.1136/jitc-2024-010568 article EN cc-by-nc-nd Journal for ImmunoTherapy of Cancer 2025-03-01

BackgroundAcquired and inherited risk factors for venous thromboembolism (VTE) the incidence of symptomatic VTE were investigated in patients on adjuvant chemotherapy breast or gastrointestinal cancer (GI).Patients methodsIn a prospective observational study (January 2003 February 2006), 199 GI (82 women/117 men; age range, 26–84 years) 182 (180 women/2 29–85 enrolled followed-up during chemotherapy. The effect acquired (i.e. age, chemotherapy, tumour histotype, history thrombosis, body mass...

10.1093/annonc/mdp354 article EN publisher-specific-oa Annals of Oncology 2009-08-28

BACKGROUND: Metabolic distress is often associated with heart failure preserved ejection fraction (HFpEF) and represents a therapeutic challenge. Metabolism-induced systemic inflammation links comorbidities HFpEF. How metabolic changes affect myocardial in the context of HFpEF not known. METHODS: We found that ApoE knockout mice fed Western diet recapitulate many features Single-cell RNA sequencing was used for expression analysis CD45 + cardiac cells to evaluate involvement diastolic...

10.1161/circulationaha.122.062984 article EN Circulation 2023-12-21

Research Article28 November 2017Open Access Transparent process Ceruloplasmin replacement therapy ameliorates neurological symptoms in a preclinical model of aceruloplasminemia Alan Zanardi Proteome Biochemistry, Division Genetics and Cell Biology, IRCCS-San Raffaele Scientific Institute, Milan, Italy Search for more papers by this author Antonio Conti Marco Cremonesi Patrizia D'Adamo Molecular Intellectual Disabilities, Neuroscience, Enrica Gilberti Unit Occupational Health Industrial...

10.15252/emmm.201708361 article EN cc-by EMBO Molecular Medicine 2017-11-28

Abstract Aim Loss of immunosuppressive response supports inflammation during atherosclerosis. We tested whether adoptive cell therapy (ACT) with Tregulatory cells (Tregs), engineered to selectively migrate in the atherosclerotic plaque, would dampen immune-inflammatory arterial wall animal models familial hypercholesterolaemia (FH). Methods and results FH patients presented a decreased Treg suppressive function associated an increased inflammatory burden. A similar phenotype was observed...

10.1093/cvr/cvaa264 article EN Cardiovascular Research 2020-09-03

Invariant natural killer T [iNKT] cells perform pleiotropic functions in different tissues by secreting a vast array of pro-inflammatory and cytotoxic molecules. However, the presence function human intestinal iNKT capable immunomodulatory molecules such as IL-10 has never been reported so far. Here we describe for first time IL10-producing [NKT10 cells] lamina propria healthy individuals Crohn's disease [CD] patients.Frequency phenotype NKT10 were analysed ex vivo from specimens [n = 17]...

10.1093/ecco-jcc/jjac049 article EN cc-by-nc Journal of Crohn s and Colitis 2022-03-25

Immunometabolism contributes to the development of metabolic diseases. Yet, how certain disorders, such as insulin deficiency (ID), influence immune cell function is poorly understood. Here, we observe that ID rearranges landscape liver, causing a decrease in T cells and an increase Kupffer cells, accompanied by shift transcriptome polarization latter. Treating mice with protein S100A9 rescues lipid-related changes caused KCs, hypertriglyceridemia hyperketonemia TLR4-dependent manner....

10.1101/2025.05.21.655283 preprint EN bioRxiv (Cold Spring Harbor Laboratory) 2025-05-27

BACKGROUND: Heart failure (HF) is strongly associated with inflammation. In pressure overload (PO)–induced HF, cardiac stress triggers adaptive immunity, ablation, or inhibition, which blocks disease progression. We hypothesized that PO-HF might fulfill the often-used criteria of autoimmunity: if so, immune response would be not only necessary but also sufficient to induce HF; it should possible identify self-antigens driving autoimmune response. Finally, we such an antigen-specific can...

10.1161/circresaha.124.324999 article EN Circulation Research 2024-12-04

Abstract: Cancer pain is often suboptimally managed. The underestimation and undertreatment continues to be a problem despite the availability of consensus-based guidelines. Most patients with cancer develop pain. prevalence severity among varies according primary metastatic sites stage disease. Opioid therapy cornerstone management severe chronic in field general palliative care medicine. Since this class drugs treatment, optimizing its use may useful clinical practice. For purpose we...

10.2147/tcrm.2006.2.4.447 article EN Therapeutics and Clinical Risk Management 2006-12-01

6014 Background: Concurrent chemoradiotherapy (CTRT) or RT + cetuximab (RT CET) are both treatment options for the of locally advanced head and neck cancer (HNC). The efficacy these two modalities patients with locoregionally inoperable HNC however has never been compared. Methods: We conducted a systematic review meta-analysis by searching in PubMED, EMBASE, SCOPUS, Web Science Cochrane Register Controlled Trials, to compare CTRT CET HNC. Risk ratios (RRs) 95% confidence intervals (95%CIs)...

10.1200/jco.2014.32.15_suppl.6014 article EN Journal of Clinical Oncology 2014-05-20
Fausto Roila Benedetta Ruggeri Enzo Ballatori L. Patoia Salvatore Palazzo and 95 more Giuseppe Colucci Francesco Di Costanzo Stefano Cascinu Roberto Labianca Alberto F. Sobrero Enrico Cortesi Caterina Bressi Roberta Ferraldeschi M. Mazzoli Maurizio Evangelista C. Di Fonzo S. Cigolari Valentina Angelini Antonio Cioffi Vincenzo Guardasole E. Zarra Maurizio Tonato Maura Betti Francesca Marrocolo V. Bon-ciarelli Gian Luigi Cetto V. Silingardi F. Cognetti Giordano Beretta A. Pessi Stefania Mosconi Laura Milesi Oscar Bertetto P Malacarne M. Marzola Guido Margutti Caterina Modenesi P. Manente Alessandro Comandone C. Oliva P. Berniolo Simona Chiadò Cutin G Luporini Giuseppe Colucci E. Recaldin M. Nicodemo Vincenzo Picece Monica Turazza E. Ferrazzi Gaspare Solina G. Rosati Antônio Rossi Luigi Manzione Pietro Sozzi Giuseppe Fornarini A Lavarello G. Catalano Paolo Giordani Paolo Alessandroni G Troccoli G. Vietti Ramus L. Tonda M.P. Sirgiovanni Giulio Iannello Vincenza Tinessa A Ruggiero S. Palazzo Sandro Barni Mario Mandalà M. Cremonesi Gianfranco Porcile M. Destefanis Franco Testore Giacomo Cartenì Bruno Daniele Carlo Alberto Volta F. Ferraù A. Zaniboni Paolo Marchetti G Citone Giampiero Ausili Cèfaro Carmine U. Iacono Marco Musi Alessandro Mozzicafreddo Francesca Imperiale G. Filippelli V. Sciacca Modesto DʼAprile Liza Mohd Isa F. Recchia Sheila Spada Stefano Cascinu R. Carroccio Giorgio Mustacchi Rita Ceccherini Maria Concetta Chetrì Paolo Boscolo‐Rizzo M Botturi P Marchei S. Bretti

Rarely are conclusions from clinical trials summarized in international consensus conferences and promptly transferred to patient care. The adjuvant therapy for colorectal cancer used daily practice Italy is described compared with the recommendations of 1990 NIH Consensus Conference.We audited prescriptions systemic therapies Italian patients 82 centers during a fixed one-week period.Among 434 receiving chemotherapy there were 139 (42.5%) colon N- 169 (51.7%) N+ regional nodal involvement....

10.1177/030089160509100605 article EN Tumori Journal 2005-11-01

Chemotherapy regimens for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) provide typically palliation limited symptom-free survival. We investigated the efficacy, in terms of response rate and time to progression, a combination chemotherapy containing carboplatin vinorelbine as first-line treatment inoperable NSCLC. Fifty-two consecutive NSCLC were treated AUC 6 according Calvert’s formula on day 1, combined vinorelbine, 25 mg/m<sup>2</sup> days 1...

10.1159/000067765 article EN Oncology 2003-01-01
Coming Soon ...